Welcome to our dedicated page for ARTIVA BIOTHERAPEUTICS news (Ticker: ARTV), a resource for investors and traders seeking the latest updates and insights on ARTIVA BIOTHERAPEUTICS stock.
Artiva Biotherapeutics develops cell therapies for autoimmune diseases and cancers, led by AlloNK® (AB-101), an allogeneic, off-the-shelf, non-genetically modified and cryopreserved NK cell therapy candidate. Company updates center on AlloNK clinical data in B-cell driven autoimmune diseases, including rheumatoid arthritis and Sjögren’s disease, and on its use with anti-CD20 monoclonal antibodies such as rituximab or obinutuzumab to drive B-cell depletion.
Recurring developments also cover quarterly and annual financial results, balance sheet disclosures, biotechnology conference participation, board and executive appointments, and equity award activity tied to Artiva’s public-company governance.
Artiva Biotherapeutics (Nasdaq: ARTV) priced an underwritten offering expected to raise approximately $300 million of gross proceeds through the sale of 23,871,526 common shares at $11.52 per share and pre-funded warrants for 2,170,138 shares at $11.5199 per share.
The offering is expected to close on or about May 11, 2026, subject to customary closing conditions; proceeds are stated before underwriting discounts, commissions and offering expenses.
Artiva Biotherapeutics (Nasdaq: ARTV) reported initial Phase 2a AlloNK (AB-101) data showing a 71% ACR50 rate in refractory rheumatoid arthritis patients with ≥6 months follow-up and complete deep B‑cell depletion in evaluable RA patients. The company secured FDA alignment on a single Phase 3 registrational trial (AlloNK + rituximab vs rituximab; ~150 patients; ACR50 at six months). Artiva had $86.8M cash, cash equivalents and investments as of March 31, 2026, expected to fund operations into Q2 2027. Multiple presentations are planned for EULAR 2026.
Artiva (Nasdaq: ARTV) reported initial clinical data showing a 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with six months of follow-up in a company-sponsored Phase 2a basket trial and FDA alignment to start a single Phase 3 registrational randomized trial in H2 2026.
As of April 3, 2026, >70 autoimmune patients treated across >40 sites; planned Phase 3 ~150 refractory RA patients, randomized 2:1 AlloNK plus rituximab vs rituximab, primary endpoint ACR50 at six months.
Artiva Biotherapeutics (Nasdaq: ARTV) said its management will participate in a panel and a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026 at 2:15 p.m. EDT.
Audio webcast and archived recording will be available via the company's Investors page and remain available for replay for 90 days.
Artiva Biotherapeutics (Nasdaq: ARTV) reported full‑year 2025 results and clinical progress on AlloNK. Key points: cash, cash equivalents and investments of $108.0 million (expected to fund operations into Q2 2027), net loss of $83.9 million, and R&D spend of $69.5 million in 2025.
Clinical updates: FDA Fast Track designation in refractory RA; initial clinical response data from at least 15 RA patients expected in H1 2026; planned FDA interaction in H1 2026 to discuss a potential pivotal trial; Phase 1/2 lymphoma data showed 64% complete response and median duration of response >19.4 months.
Artiva Biotherapeutics (Nasdaq: ARTV) announced management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 4, 2026 at 1:10 p.m. EST in Boston.
Artiva management will meet registered investors and the audio webcast plus archived recording will be available on the company investor website for 90 days.
Artiva (Nasdaq: ARTV) appointed Thad Huston as Chief Financial Officer and approved a 220,000 restricted stock unit inducement grant. Mr. Huston brings over 30 years of finance, commercial and operations leadership, including roles at Galapagos and Kite Pharma.
The RSUs vest over four years, contingent on filing a Form S-8, and Artiva says the hire supports progress toward FDA feedback and rheumatoid arthritis clinical data in H1 2026.
Artiva Biotherapeutics (Nasdaq: ARTV) appointed Elaine Sorg to its board on Feb 19, 2026. Ms. Sorg brings 35+ years of commercial biopharma experience, including leading U.S. commercialization for major immunology therapies.
The company said her expertise will support upcoming clinical activity readouts for AlloNK in rheumatoid arthritis and engagement with the FDA on a registrational trial.
Artiva Biotherapeutics (Nasdaq: ARTV) will present at the 2026 Transplantation & Cellular Therapy Tandem Meetings in Salt Lake City, Feb 4–7, 2026. Artiva will feature poster presentations on Feb 5, 2026 at 6:30 pm MST covering: the cost-effectiveness of AB-101/AlloNK administered in an outpatient community rheumatology practice versus CAR-T treatments, and continued durability data for AlloNK in relapsed/refractory Non-Hodgkin Lymphoma from a multi-center Phase 1/2 trial. Poster IDs are 440 (health services/cost-effectiveness) and 511 (lymphoma clinical durability); authors listed include Nicholas Veomett, Ph.D. and Umer Farooq, M.D. For full abstracts, consult the 2026 Tandem Meetings program.
NanoSyrinx (ARTV) appointed Thomas J. Farrell as Chief Executive Officer and Director effective Jan 8, 2026, succeeding founder Joe Healey, who will remain involved to ensure continuity.
Farrell brings 25+ years in biotherapeutics, served as founding CEO of two NASDAQ-listed companies, raised over $500 million in financing, and has led programs from discovery through clinical trials. NanoSyrinx is transitioning from platform development to building a clinical pipeline for its Nanosyringe intracellular delivery technology, which enables direct cytosolic delivery of protein therapeutics. Farrell will be in San Francisco during the J.P. Morgan Healthcare Conference (Jan 12–15, 2026) and is available for investor and partner discussions.